DeepMed Research

INSTITUT CLAUDIUS REGAUD

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.claudiusregaud.fr

Clinical Trials

Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Malignant Solid Tumour

Interventions: Drug: Zolinza (vorinostat), vinorelbine

First Posted Date: 2008-12-03

Last Posted Date: 2010-05-20

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 30

Registration Number: NCT00801151

Locations: 🇫🇷
Centre René GAUDUCHEAU, Nantes Saint Herblain, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut Claudius REGAUD, Toulouse, France

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

Not Applicable

Suspended

Conditions: Chemotherapeutic Agent Toxicity
Renal Toxicity
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-06-11

Last Posted Date: 2014-11-05

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 80

Registration Number: NCT00695032

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France

Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

Phase 3

Completed

Conditions: Breast Neoplasms

First Posted Date: 2005-12-22

Last Posted Date: 2009-03-18

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 347

Registration Number: NCT00268125

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Centre Paul STRAUSS, Strasbourg, France
🇫🇷
Centre Oscar Lambret, Lille, France

Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage

Phase 3

Completed

Conditions: Vulvar Neoplasms
Skin Neoplasms

Interventions: Device: ultracision
Device: classical lymphadenectomy

First Posted Date: 2005-09-23

Last Posted Date: 2014-09-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 73

Registration Number: NCT00224744

Locations: 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Phase 2

Completed

Conditions: Genital Neoplasms, Male

First Posted Date: 2005-09-21

Last Posted Date: 2015-03-31

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 50

Registration Number: NCT00210041

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Institut Bergonie, Bordeaux, France

and more 8 locations

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

First Posted Date: 2005-09-21

Last Posted Date: 2011-11-24

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 27

Registration Number: NCT00209989

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Centre Jean Perrin, Clermont Ferrand, France

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

Phase 2

Terminated

Conditions: Neoplasms
Anemia

First Posted Date: 2005-09-21

Last Posted Date: 2006-11-14

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 55

Registration Number: NCT00210002

Locations: 🇫🇷
Centre Hospitalier de Montauban, Montauban, France
🇫🇷
Centre Hospitalier Joseph Ducuing, Toulouse, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

and more 1 locations

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms

First Posted Date: 2005-09-21

Last Posted Date: 2006-11-14

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 40

Registration Number: NCT00210028

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Institut Val d'Aurelle_ Paul Lamarque, Montpellier, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

Determination of Carboplatin's Optimal Plasmatic Exposure

Not Applicable

Completed

Conditions: Neoplasms

First Posted Date: 2005-09-05

Last Posted Date: 2009-03-18

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 400

Registration Number: NCT00145028

Locations: 🇫🇷
CHU A. Michallon, Grenoble, France
🇫🇷
Centre Oscar Lambert, Lille, France
🇫🇷
Centre Paul Papin, Angers, France

and more 12 locations

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Not Applicable

Completed

Conditions: Head and Neck Neoplasms

First Posted Date: 2005-09-05

Last Posted Date: 2015-03-27

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 43

Registration Number: NCT00144976

Locations: 🇫🇷
Center Oscar Lambret, Lille, France
🇫🇷
Institut claudius regaud, Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy